Indication Prioritization: Aligning on Priority Indications for an Early Asset
The clinical and commercial teams in the oncology division of a Top 20 pharma company were struggling to align on which indications to develop their early stage assets in. As a result, most of the company’s Ph1 trials were large, all-comer trials, which slowed product development and eliminated many fast-to-market opportunities. Artisan was brought in to help identify commercially viable indications and development pathways for an early asset and foster cross-functional alignment.
© 2020 SOURCE EXPLORER®. All rights reserved.